Herbalife Nutrition Ltd vs Immunovant Inc. Common Stock — how do they compare? Herbalife Nutrition Ltd trades at $13.03 (market cap $1.34B), while Immunovant Inc. Common Stock trades at $30.5 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is far larger — about 4.7× Herbalife Nutrition Ltd's market cap, and Immunovant Inc. Common Stock is more actively traded (1,755,411 versus 1,589,457). Which is the better fit depends on your goals — on Pluang, investors hold Herbalife Nutrition Ltd for 43 Days and Immunovant Inc. Common Stock for 1 Days on average.
| HLF | IMVT | |
|---|---|---|
Market Cap | $1.34B | $6.25B |
Volume | 1,589,457 | 1,755,411 |
Sector | Consumer Staples | Health |
52-Week High | $19.96 | $44.96 |
52-Week Low | $7.75 | $17.03 |
Typical Hold Time | 43 Days | 1 Days |
Enterprise Value | $3.18B | $5.35B |
Signals from Pluang's Aura AI — not financial advice
Herbalife (HLF) trades at $13.03, up 3.0% with a bullish technical signal. The stock shows attractive valuation metrics with P/E of 8.22 and P/S of 0.26, while maintaining strong gross margins of 77.7%. Recent Q1 2026 earnings beat expectations, though Q2 2026 missed. The company announced a $250 million share repurchase program and CEO transition, with management reaffirming 2026 guidance. Cash flow trends show improvement with projected positive net cash flow of $50 million for 2026.
HLF presents a value opportunity with discounted valuation and improving debt profile, though execution risks remain. Analyst consensus targets $19.00 (53.8% upside) with 14 buy ratings. Key risks include mixed earnings performance, high debt levels despite recent reduction, and leadership transition. The stock offers potential for re-rating if management delivers on margin expansion and growth targets outlined in recent investor presentations.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →